Li J - Search Results

1

Biomarker-driven targeted therapy in patients with recurrent platinum-resistant epithelial ovarian cancer (BRIGHT): protocol for an open-label, multicenter, umbrella study.

Xu Y, Xiong F, Li H, Zheng H, Jiang J, Li Q, Li G, Zhao W, Li R, Li J, Xie R, An R, Zhang H, Gao Q. Xu Y, et al. Among authors: li j, li g, li h, li q, li r. Int J Gynecol Cancer. 2024 Apr 23:ijgc-2024-005351. doi: 10.1136/ijgc-2024-005351. Online ahead of print. Int J Gynecol Cancer. 2024. PMID: 38658024

2

Survival Impact of Ovarian Preservation on Women With Early-Stage Endometrial Cancer: A Systematic Review and Meta-analysis.

Gu H, Li J, Gu Y, Tu H, Zhou Y, Liu J. Gu H, et al. Among authors: li j. Int J Gynecol Cancer. 2017 Jan;27(1):77-84. doi: 10.1097/IGC.0000000000000857. Int J Gynecol Cancer. 2017. PMID: 27922977 Review.

3

Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial.

Lan C, Shen J, Wang Y, Li J, Liu Z, He M, Cao X, Ling J, Huang J, Zheng M, Zou G, Yan H, Liu Q, Yang F, Wei W, Deng Y, Xiong Y, Huang X. Lan C, et al. Among authors: li j. J Clin Oncol. 2020 Dec 1;38(34):4095-4106. doi: 10.1200/JCO.20.01920. Epub 2020 Oct 14. J Clin Oncol. 2020. PMID: 33052760 Free PMC article. Clinical Trial.

4

The first Chinese National Union of Real-world Gynaecological Oncology Research and Patient Management Platform: A retrospective study.

Zeng S, Chi J, Liu J, Jiao X, Liu X, Yu Y, Li R, Huo Y, Ma G, Zhao Y, Wang L, Zhou Q, Zou D, Cheng X, Li Q, Wang J, Yao S, Zhao W, Xia B, Chen Y, Fan J, Wang W, Hong L, Guo R, Liu Z, Gao Y, Li J, Zhang B, Yu J, Hu T, Zhang W, Shan W, Peng Z, Li M, Xie X, Ma D, Gao Q. Zeng S, et al. Among authors: li j, li m, li q, li r. BJOG. 2022 Nov;129 Suppl 2:60-69. doi: 10.1111/1471-0528.17328. BJOG. 2022. PMID: 36485066

5

A novel combination of niraparib and anlotinib in platinum-resistant ovarian cancer: Efficacy and safety results from the phase II, multi-center ANNIE study.

Liu G, Feng Y, Li J, Deng T, Yin A, Yan L, Zheng M, Xiong Y, Li J, Huang Y, Zhang C, Huang H, Wan T, Huang Q, Lin A, Jiang J, Kong B, Liu J. Liu G, et al. Among authors: li j. EClinicalMedicine. 2022 Nov 30;54:101767. doi: 10.1016/j.eclinm.2022.101767. eCollection 2022 Dec. EClinicalMedicine. 2022. PMID: 36583171 Free PMC article.

6

[Phase II clinical study of topotecan hydrochloride in patients with recurrent advanced ovarian cancer].

Li JD, Guan ZZ, Liu JH, Xin XY, Cui Y, Huang CJ, Liu FY, Song L, Bian ML, Zhou QH. Li JD, et al. Ai Zheng. 2002 Apr;21(4):416-20. Ai Zheng. 2002. PMID: 12452024 Clinical Trial. Chinese.

7

Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study.

Lan CY, Wang Y, Xiong Y, Li JD, Shen JX, Li YF, Zheng M, Zhang YN, Feng YL, Liu Q, Huang HQ, Huang X. Lan CY, et al. Lancet Oncol. 2018 Sep;19(9):1239-1246. doi: 10.1016/S1470-2045(18)30349-8. Epub 2018 Aug 3. Lancet Oncol. 2018. PMID: 30082170 Clinical Trial.

8

Adipose tissue area as a predictor for the efficacy of apatinib in platinum-resistant ovarian cancer: an exploratory imaging biomarker analysis of the AEROC trial.

Huang X, Xie C, Tang J, He W, Yang F, Tian W, Li J, Yang Q, Shen J, Xia L, Lan C. Huang X, et al. Among authors: li j. BMC Med. 2020 Oct 5;18(1):267. doi: 10.1186/s12916-020-01733-4. BMC Med. 2020. PMID: 33012286 Free PMC article.

9

Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer.

Wei W, Ban X, Yang F, Li J, Cheng X, Zhang R, Huang X, Huang Y, Li Q, Qiu Y, Zheng M, Zhu X, Li J. Wei W, et al. Among authors: li j, li q. J Immunother Cancer. 2022 May;10(5):e004338. doi: 10.1136/jitc-2021-004338. J Immunother Cancer. 2022. PMID: 35623659 Free PMC article. Clinical Trial.

10

The MYBL2-CCL2 axis promotes tumor progression and resistance to anti-PD-1 therapy in ovarian cancer by inducing immunosuppressive macrophages.

Pan B, Wan T, Zhou Y, Huang S, Yuan L, Jiang Y, Zheng X, Liu P, Xiang H, Ju M, Luo R, Jia W, Lan C, Li J, Zheng M. Pan B, et al. Among authors: li j. Cancer Cell Int. 2023 Oct 21;23(1):248. doi: 10.1186/s12935-023-03079-2. Cancer Cell Int. 2023. PMID: 37865750 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

179,496 results

Search Page